USA flag logo/image

An Official Website of the United States Government

Natural Product Screening for Prostate Cancer Therapeutics Using Gene Expression

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
88854
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
CA128144
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
NUVOGEN RESEARCH, LLC
PO Box 64326 Tucson, AZ 85728-0000
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: Natural Product Screening for Prostate Cancer Therapeutics Using Gene Expression
Agency: HHS
Contract: 1R43CA128144-01A1
Award Amount: $162,191.00
 

Abstract:

DESCRIPTION (provided by applicant): In Phase I, newly available natural product extracts will be tested to find compounds that specifically target genes that are critical for the androgen receptor pathway of growth stimulation in recurrent prostate cancer s. This is important because the androgen receptor pathway is deregulated and critical to recurrent metastatic prostate cancer, even in the absence of androgen. Interestingly recurrent tumors are androgen independent, but the androgen receptor pathway rega ins a critically active regulatory role through various molecular mechanisms. A quantitative high-throughput gene chip assay, ArrayPlate, will test for products that reverse the gene expression pattern for 30 genes affected by androgen activation of androg en dependent prostate cancer cells to the inactive state. The extracts are derived from Sonoran desert plants and associated microorganisms recently discovered by the Southwest Center for Natural Product Research and Commercialization, at the University of Arizona. Phase II will follow up on reconfirmed hit fractions identified in Phase I. Fractions will be further fractionated and retested with the same assay to attempt to isolate and identify the active compounds, and compounds with sufficient activity wi ll be tested in vitro and in vivo on different kinds of androgen independent recurrent prostate cancer cells. Novel therapeutics that target the various mechanisms by which recurrent tumors have acquired androgen independence, but maintained dependence upo n the androgen receptor activation pathway will have a major therapeutic impact for patients with recurrent, hormone-refractory prostate cancer. Due to earlier detection and increased life expectancy prostate cancer is rapidly becoming the most frequent so lid cancer in older men and the second leading cancer killer of men. The majority of patients die from PCa as a result of hormone-refractory disease, since no alternative therapy is currently available to treat hormone-refractory, metastatic PCa. There is great potential for the discovery of novel therapeutics from natural products. The natural products used in this grant are from the southwest and may be an untapped source of novel therapies for prostate cancer.

Principal Investigator:

Business Contact:


rkris@nuvogenresearch.com
Small Business Information at Submission:

NUVOGEN RESEARCH, LLC
NUVOGEN RESEARCH, LLC BOX 64326 TUCSON, AZ 85728

EIN/Tax ID: 860897386
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No